Enanta Pharmaceuticals to Participate in Two Investor Conferences in June

Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) announced participation in two virtual investor conferences in June 2021. Jay R. Luly, Ph.D., President and CEO, will engage in a fireside chat at the JMP Securities Life Sciences Conference on June 17 at 10:30 a.m. ET and present at the Raymond James Human Health Innovation Conference on June 21 at 10:40 a.m. ET. Webcasts will be accessible on Enanta's 'Events and Presentations' page, and replays will be archived for 30 days. The company focuses on small molecule drugs for viral infections and liver diseases.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two virtual investor conferences being webcast in June:

• The JMP Securities Life Sciences Conference: Fireside Chat at 10:30 a.m. ET on June 17, 2021
• Raymond James Human Health Innovation Conference: Presentation at 10:40 a.m. ET on June 21, 2021

A live webcast of each event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. Replays of the webcasts will be available following the presentations and will be archived for at least 30 days.

About Enanta

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). Enanta is also conducting research in SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210610005027/en/

FAQ

What are the details of Enanta Pharmaceuticals' participation in the June 2021 investor conferences?

Enanta Pharmaceuticals will participate in two events: a fireside chat at the JMP Securities Life Sciences Conference on June 17, 2021, at 10:30 a.m. ET and a presentation at the Raymond James Human Health Innovation Conference on June 21, 2021, at 10:40 a.m. ET.

Where can I watch the live webcasts for Enanta Pharmaceuticals' investor conferences?

The live webcasts can be accessed on Enanta's 'Events and Presentations' page on their website, www.enanta.com.

Will the presentations from Enanta's investor conferences be available for later viewing?

Yes, replays of the webcasts will be available for at least 30 days after each presentation.

What is Enanta Pharmaceuticals focused on in their research and development?

Enanta Pharmaceuticals specializes in developing small molecule drugs for viral infections and liver diseases, targeting pathogens like RSV, HBV, and NASH.

How is Enanta Pharmaceuticals funded?

Enanta's research and development activities are funded by royalties from hepatitis C virus products developed in collaboration with AbbVie.